據報新加坡生物科企覓萃不排除在港融資
據《明報》報道,以新加坡爲基地的生物科技企業覓萃(MiRXES),去年11月起落戶香港並設立辦事處,其香港董事總經理羅文達表示,公司不排除任何進一步併購及融資的可能性,而香港的資本融資市場更是其中考慮之列。
他表示,公司現時其早篩病症的方案,主要適用於檢測癌症、心血管疾病、代謝疾病和感染性疾病,適應的病症涵蓋胃癌、大腸癌及難以發現的胰臟癌等病症。
他續指,由於公司具備廠房設施,期望最終生產出更便宜的早篩病症工具,幫助更多病患人士;現時其產品透過保險公司及體檢機構作爲渠道,覆蓋45個國家及地區市場。
羅文達稱,在港的辦事處可容納15至20人的團隊,有助部署進一步進入大灣區市場;盼在港發展會與新加坡總部相輔相成,甚至在將來設實驗室做好開發。他更認爲對公司而言,香港的資本及融資市場發展不俗,可供公司日後考慮。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.